Pharmacological Management of Depression in Youth

Depression in children and adolescents represents a major public health challenge, with onset often occurring during critical developmental periods. Pharmacological intervention is central to management when depressive symptoms are moderate to severe or when psychosocial treatments alone prove insufficient. Selective serotonin reuptake inhibitors (SSRIs) are generally regarded as first-line agents, with fluoxetine most frequently recommended due to its favourable risk–benefit profile in younger populations. Other classes, including serotonin and norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants (TCAs), may be considered in cases of partial response or intolerance, but require careful monitoring for side effects and overdose risk. Dosing strategies typically begin at the lower end of the therapeutic range, with gradual titration informed by clinical response and tolerability. Adverse effects such as gastrointestinal disturbance, sleep disruption and, rarely, increased agitation or suicidal ideation are monitored through regular clinical review, ideally supplemented by rating scales and collateral reports from families or schools. In treatment-resistant cases, augmentation with atypical antipsychotics or combination with psychotherapy may be indicated. Ethical and regulatory frameworks emphasise shared decision-making, informed consent and age-appropriate communication. Globally, variations in prescribing patterns reflect differences in guideline adoption, healthcare access and cultural attitudes, underscoring the need for harmonised standards and training. Ongoing research seeks to refine biomarkers of response, optimise dosing algorithms and integrate digital monitoring to enhance safety and efficacy in this vulnerable group.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Management of Depression in Youth publication trend

The graph below shows the total number of articles in pharmacological management of depression in youth across all publications each year (not limited to Nature Index journals).

Technical terms

Selective serotonin reuptake inhibitor (SSRI): class of antidepressants that increase synaptic serotonin levels by inhibiting its reuptake.
Tricyclic antidepressant (TCA): older class of antidepressants which block the reuptake of noradrenaline and serotonin, often associated with anticholinergic effects.
Serotonin and norepinephrine reuptake inhibitor (SNRI): antidepressants that inhibit the reuptake of both serotonin and noradrenaline, used when SSRIs are insufficient.
Remission: the absence of clinically significant symptoms of depression following treatment.
Treatment-resistant depression: depressive disorder unresponsive to at least two adequate trials of different antidepressant classes.

References

1. Seasonal trends in antidepressant prescribing, depression, anxiety and self-harm in adolescents and young adults: an open cohort study using English primary care data. BMJ Mental Health (2023).
2. Treatment patterns of antidepressants in children and adolescents in Scandinavia. European Child & Adolescent Psychiatry (2024).